JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$269.99
−0.09%Jun 11, 2026, 11:45 UTC
Johnson & Johnson expanded U.S. availability of its TECNIS PureSee IOL, an advanced lens option for cataract surgeons and patients.
Source:Jun 11, 2026, 06:03 UTC
Johnson & Johnson presented pivotal Phase 2/3 study results for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia at EHA 2026 in Stockholm.
Source:Jun 10, 2026, 15:22 UTC
A Los Angeles jury awarded $32 million to the family of Maria Lozano, finding Johnson & Johnson liable for her mesothelioma from asbestos-contaminated talc.
Source:Jun 8, 2026, 12:00 UTC
Johnson & Johnson has agreed to acquire Firefly Bio, Inc. for $1 billion in cash.
Jun 6, 2026, 01:56 UTC
A California jury reached a defense verdict in favor of Johnson & Johnson in the second bellwether ovarian cancer talcum powder trial in Los Angeles.
Jun 3, 2026, 04:04 UTC
Johnson & Johnson announced that nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, with results presented at a conference.
Source:Jun 2, 2026, 10:30 UTC
LISTERINE introduced a new range of mouthwash intensities, including Extra Mild, available nationwide as of June 2, 2026.
Jun 1, 2026, 02:03 UTC
Legend Biotech held an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma.
Source:May 31, 2026, 13:00 UTC
Johnson & Johnson announced Phase 3 study results for ERLEADA (apalutamide) in prostate cancer, showing reduced risk of metastasis or death.
Source:May 31, 2026, 12:29 UTC
Johnson & Johnson announced pivotal results from the OrigAMI-4 study for RYBREVANT FASPRO in advanced head and neck cancer.
Source:
← PreviousPage 3